LENZ Therapeutics Develops Aceclidine Eye Drops for Presbyopia

LENZ Therapeutics Advances Aceclidine-Based Eye Drops for Presbyopia

LENZ Therapeutics is making significant strides in the development of LNZ100, an innovative aceclidine-based eye drop aimed at improving near vision in patients with presbyopia. This condition affects approximately 1.8 billion people worldwide, including 128 million in the United States. LNZ100, a preservative-free, single-use, once-daily eye drop, has been evaluated in the Phase 3 CLARITY study. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100.

Aceclidine stands out from other miotics due to its pupil-selective mechanism, which induces miosis without overstimulating the ciliary muscles, thus preventing a myopic shift that could impair distance vision. This makes LNZ100 particularly beneficial for older presbyopes who have lost lens accommodation capacity. Clinical testing suggests that users may benefit from LNZ100 from their mid-40s to mid-70s, regardless of refractive errors.

CORXEL, formerly Ji Xing Pharmaceuticals, is a biotech company dedicated to developing innovative treatments for cardiometabolic diseases. Founded in 2019 and backed by RTW Investments, CORXEL has a portfolio that includes global rights to JX09 for hypertension and JX10 for acute ischemic stroke, as well as Greater China rights to several other assets.

LENZ Therapeutics is committed to providing a pharmaceutical solution that enhances vision all day for presbyopia patients. Headquartered in San Diego, California, LENZ is preparing to commercialize LNZ100, pending FDA approval.

For more information, visit LENZ Therapeutics and CORXEL.